spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  IL-2 

 HSMN NewsFeed - 25 Aug 2025
Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4R?) for Atopic Dermatitis Achieve Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 30 May 2025
Diakonos Oncology Closes $20 Million Financing to Accelerate Phase 2 Glioblastoma Clinical Development Program and Expand Use of Innovative Dendritic Cell Platform for Studies in Other Indications
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 7 Feb 2025
Most Patients on Lilly's Omvoh(R) (mirikizumab-mrkz) for Crohn's Disease Achieved Sustained Clinical Remission and Endoscopic Response at Two Years
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 16 Aug 2024
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Feb 2024
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2023
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Sep 2023
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Sep 2022
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI(R)) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 7 Apr 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE(TM) Molecule
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Mar 2022
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Mar 2022
Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Dec 2021
Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Sep 2021
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology
Biopharmaceutical Gastroenterology Personnel
 HSMN NewsFeed - 9 Aug 2021
SKYRIZI(R) (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Product Launch
 HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jun 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Mar 2021
Bioniz Therapeutics Appoints Dr. Alexandre Kaoukhov to Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Mar 2021
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jan 2021
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Oct 2020
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jul 2020
Lilly's Mirikizumab Superior to Cosentyx(R) (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2020
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 3 Oct 2019
New Head-to-Head Data Show Taltz(R) (ixekizumab) Superiority versus TREMFYA(R) (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 1 Oct 2019
Nektar Announces Key Executive Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals
 HSMN NewsFeed - 3 Jun 2019
Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 May 2019
GenePOC Obtains FDA Clearance for its GenePOC(TM) Carba Test in the US
Diagnostics FDA
 HSMN NewsFeed - 26 Mar 2019
AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Mar 2019
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 13 Sep 2018
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 10 Sep 2018
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz(R) and Tremfya(R) in Patients with Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 16 Aug 2018
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jul 2018
Synthorx Expands Leadership Team with Three Key Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2018
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Apr 2018
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin(TM) Cytokines
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 15 Sep 2017
Janssen Receives CHMP Positive Opinion for Guselkumab Recommending Approval for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 30 May 2017
Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. for Oral Interleukin-23 Receptor Antagonist Drug Candidate for the Treatment of Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 24 May 2017
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Jan 2017
Immune Pharmaceuticals Appoints New Chairman of the Board of Directors
Biopharmaceuticals Gastroenterology Oncology Personnel
 HSMN NewsFeed - 26 Jan 2017
Celgene to Acquire Delinia, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Dec 2016
Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 14 Dec 2016
Health Canada approves STELARA(R) for the treatment of adults with moderately to severely active Crohn's disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 9 Dec 2016
Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA(TM) (Daclizumab Beta) for Multiple Sclerosis
Biopharmaceuticals Nerurology Regulatory
 HSMN NewsFeed - 3 Oct 2016
Allergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 10 Sep 2015
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 17 Aug 2015
European Commission Grants Marketing Authorisation for Unituxin(TM) (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 May 2015
Provectus Biopharmaceuticals Updates Market on Business Developments
Biopharmaceuticals Dermatology Oncology
 HSMN NewsFeed - 20 Aug 2013
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Feb 2013
EpiCept Corporation and Immune Pharmaceuticals Amend Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Nov 2012
Immune Pharmaceuticals and EpiCept Corporation Agree to Merge
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Sep 2012
EpiCept Regains Rights to Azixa(R) from Licensee Myrexis
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 6 Jul 2011
Coronado Biosciences Closes $25.8M in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Mar 2011
EpiCept Identifies Ceplene(R) Survival Benefit in Key AML Subgroup
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2010
EpiCept Announces Ceplene(R) Approved for Marketing in Israel
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Oct 2010
EpiCept Corporation and FDA Agree on Development Plan for Ceplene(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2010
New Data Demonstrate Treatment With STELARA(R) (Black Triangle Drug) (ustekinumab) Results in Sustained Improvements in Psoriasis Severity and Quality of Life up to Three Years
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 7 Sep 2010
Bristol-Myers Squibb to Acquire ZymoGenetics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 May 2010
STELARA(TM) Significantly Improves Symptoms of Depression, Anxiety and Health-Related Quality of Life in Patients With Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 1 Mar 2010
FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 26 Jan 2010
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 14 Jan 2010
STELARA(TM) (ustekinumab) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Jan 2010
BioVex Appoints Tim Hanke as VP Commercial Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Sep 2009
Janssen-Cilag's STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 10 Jul 2009
EpiCept Initiates Post-Approval Clinical Study with Ceplene(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2009
Synta Restructures Organization to Focus on New Priorities
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Oct 2008
EpiCept Receives Ceplene(R) Marketing Approval in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Sep 2008
Findings From Landmark Study Show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 8 Aug 2008
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Aug 2008
Curacyte Sells Its Subsidiary Curacyte Discovery GmbH to The Medicines Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Aug 2008
The Medicines Company Acquires CU-2010 and Curacyte Discovery GmbH
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Aug 2008
TVM Capital Welcomes The Medicines Company in The European Market Through the Acquisition of Curacyte Discovery GmbH
Biopharmaceuticals Venture Capital Mergers & Acquisitions
 HSMN NewsFeed - 25 Jul 2008
Ceplene(R) Receives Positive European Opinion for Approval From CHMP
Biopharmaceuticals Regulatory Oncology
 HSMN NewsFeed - 17 Jun 2008
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 12 Jun 2008
EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free Survival as Predictor of Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 May 2008
EpiCept Files Re-Examination Documentation for Marketing Authorization of Ceplene(TM) in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Apr 2008
VioQuest Pharmaceuticals Names Vernon L. Alvarez, Ph.D. as Vice President, Research & Development and Announces Resignation of Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Mar 2008
EpiCept Announces Opinion by European Regulatory Authority on Ceplene(R)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Feb 2008
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Feb 2008
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Feb 2008
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 10 Dec 2007
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2007
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 13 Nov 2007
AVAX Technologies announces the initiation of its Phase III Registration trial of M-Vax(R) in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Oct 2007
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 3 Oct 2007
Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2007
EpiCept Reports Regulatory Progress on Ceplene(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
ONTAK(R) (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2007
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Dec 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2006
AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2006
EpiCept Announces Successful Validation of Marketing Authorization Application for Ceplene(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Oct 2006
Maxygen to Receive $17.8 Million From Acquisition of Avidia by Amgen
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Oct 2006
AVAX Technologies Announces Special Protocol Assessment Agreement with FDA for a Phase III Clinical Trial of M-Vax in Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Oct 2006
EpiCept Files for Marketing Approval of Ceplene(TM) in European Union
Biopharmaceuticals Oncology Regulatory
Return to NewsFeed  

 Additional items found! 54

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 54 additional stories matching:
IL-2
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!